{
    "pmcid": "9906597",
    "qa_pairs": {
        "What is a potential advantage of using non-neutralizing antibodies (non-NAbs) in the photodynamic approach described in the study?": [
            "They provide broad-spectrum recognition across different variants.",
            "They directly block the interaction with the ACE2 receptor.",
            "They exert selective pressure on the virus.",
            "They target only the RBD of the spike protein."
        ],
        "What is the primary target for neutralizing antibodies in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD)",
            "The N-terminal domain (NTD)",
            "The S2 domain",
            "The membrane fusion domain"
        ],
        "What specific amino acids in the spike protein were identified as oxidation hotspots by mass spectrometry?": [
            "Y145 and H146",
            "D614 and N501",
            "K417 and E484",
            "L452 and T478"
        ],
        "What technical challenge is associated with the photodynamic therapy approach in clinical settings?": [
            "Delivering light to deeper tissues",
            "Producing sufficient quantities of SOPP3",
            "Ensuring antibodies remain stable in vivo",
            "Preventing the generation of harmful byproducts"
        ],
        "Which photosensitizer was used in the study to enhance antibody neutralization efficacy against SARS-CoV-2?": [
            "SOPP3",
            "miniSOG",
            "Rose Bengal",
            "Hypericin"
        ]
    }
}